GLPwatch
Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
J Fam Pract · 2017
Last updated 2026-05-28The article explains why combining a long-acting insulin with a GLP-1 receptor agonist (GLP-1RA) may help treat type 2 diabetes. It includes data on using these medications together, including as a single fixed-dose injection.
AI summary of the abstract below.
| Journal | J Fam Pract, 2017 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
This article presents the rationale and data for combining a basal insulin with a GLP-1RA, including as fixed-ratio products.
Verbatim abstract via PubMed 28991933 ↗